Youjia Bio Announces Completion of Tens of Millions RMB Series A Financing Led by Boyi Fund with WinX Capital as Lead Financial Advisor

VCBeat learned第一时间that on November 15, 2021,Youjia (Hangzhou) Biomedical Technology Co., Ltd. (hereinafter referred to as "YOUJIA BIO") announced the completion of a multi-million yuan Series A financing round. This round was led by the Boyi Fund under Tasly Capital, with participation from Secret Silver Investment and Zelong Investment. WinCapital served as the chief financial advisor for this round.It is reported that the funds from this round will be mainly used to advance the IND application for preclinical projects and expand the CMC platform.

"We are delighted to have professional funds focused on the biopharmaceutical field participate in this round of financing, and we are also very grateful for the support and trust from professional institutions towards YOUJIA BIO. At the same time, we are extremely proud that our independently developed small nucleic acid drug discovery platforms—including the NDDS intelligent design system, drug druggability evaluation platform, polymer delivery system platform, and a mature formulation platform—have been recognized by top investors."Dr. Cui Wenhao, Founder and CEO of YOUJIA BIO"The completion of this round of financing will help us quickly advance the IND application of our existing product pipeline and improve the construction of our CMC platform, while promoting the establishment of a gene innovative drug R&D base co-built with Osaka University in Japan. This will form an international layout with multi-regional cooperation. With YOUJIA BIO's accumulation and execution capability in small nucleic acid drugs, we will continue to focus on the R&D of innovative drugs that meet clinical needs."

Mr. Zhu Yanfei, General Manager of Boyi Fund"We are very optimistic about the prospects of nucleic acid innovative drugs. YOUJIA BIO has a comprehensive nucleic acid drug R&D platform and a very solid foundation and rich experience in screening, delivery, and formulation. The company has an excellent team with extensive experience in R&D, process, commercialization, and capital operations. We look forward to YOUJIA BIO rapidly bringing innovative drugs with significant clinical application potential to the market for the benefit of patients."

Youjia (Hangzhou) Biomedical Technology Co., Ltd. was jointly founded by multiple returned overseas Ph.D.s and a team with rich industrialization experience. With the starting point of meeting clinical needs, the company focuses on developing innovative drugs with independent intellectual property rights. It has currently established a mature nucleic acid drug development platform, including the NDDS intelligent design system for nucleic acid drugs, a well-developed delivery system, a comprehensive drug evaluation platform, and a polymer-based multi-formulation platform. The company boasts a rich product pipeline, which has covered areas such as antiviral, anti-fibrotic, and cardiovascular diseases.

WinX Capital is a leading investment bank in China's healthcare sector. The founding team includes five global finance Ph.D.s from the PBC School of Finance at Tsinghua University, and the frontline team has an average of over 10 years of experience in management, investment, and M&A, with cumulative investment and M&A transactions exceeding 30 billion yuan. Headquartered in Beijing and Shanghai, it covers more than 3,000 active investment institutions and industry groups. In 2020, it was ranked by 36Kr as one of the "WISE 2020 Top 5 Most Growth-Potential New Investment Banks in China" and recognized by Qiming Technology & Xinsheng Chuangfu as one of the "Top 4 Best Financial Advisory Firms in the Healthcare Sector in 2020."